Disability

IDMC Provides Positive Recommendation for Bio-Thera Solution’s BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III Trial

GUANGZHOU, China, July 2, 2025 /PRNewswire/ -- Bio-Thera Solutions, Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative...

Baylor Genetics Applauds New Guidance from American Academy of Pediatrics for Genome and Exome Sequencing to be used as First-Tier Tests for Children with Certain Developmental Delays

Guidance also outlines metabolic evaluation – like Baylor Genetics’ unique Global MAPS® untargeted metabolite screen – as second-tier testHOUSTON, June...

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in...

Access Ready Strategic Joins the Consortium for Constituents with Disabilities (CCD) and Other Organizations on Vital Policy and Public Interest Positions

Many Groups and Organizations respond on Policy Issues WASHINGTON, June 12, 2025 /PRNewswire/ -- The recent rapid approach to policy...

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting...

Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis

Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two...

error: Content is protected !!